Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol
نویسندگان
چکیده
منابع مشابه
Cardiovascular Complications of Hematopoietic Stem Cell Transplantation.
OPINION STATEMENT Survivors of hematopoietic stem cell transplant (HSCT) are at significant risk for cardiac disease and cardiac complications. While there may be cardiac complications during the acute period of HSCT, long-term survivors remain at risk for cardiovascular disease at a rate at least fourfold higher than the general population. Aggressive screening for cardiac risk factors such as...
متن کاملCrystal and molecular structure of paclitaxel (taxol).
Paclitaxel (formerly called taxol), an important anticancer drug, inhibits cell replication by binding to and stabilizing microtubule polymers. As drug-receptor interactions are governed by the three-dimensional stereochemistries of both participants, we have determined the crystal structure of paclitaxel to identify its conformational preferences that may be related to biological activity. The...
متن کاملLiposomal Paclitaxel : Recent Trends and Future Perspectives
One of the most promising anti-cancer agents paclitaxel, especially effective for treatment of ovarian and breast cancer, suffers from the problems like poor water solubility and low bioavailability. The current formulation available in a non-aqueous vehicle containing Cremophor EL® (polyethoxylated castor oil), on aqueous dilution, when given intravenously, may cause allergic reactions and pre...
متن کاملHow Taxol/paclitaxel kills cancer cells
Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to...
متن کاملBiweekly paclitaxel (Taxol) and cisplatin in breast and ovarian cancer.
Two trials are being conducted to evaluate paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combined with cisplatin in previously treated and untreated breast and ovarian cancer. Preliminary results are presented. The objectives of these nonrandomized trials are (1) to determine the toxicity of paclitaxel/cisplatin in a biweekly schedule, (2) to establish the maximum tolerated do...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Oncology
سال: 2018
ISSN: 1019-6439,1791-2423
DOI: 10.3892/ijo.2018.4449